Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Author:

Gaylis Norman B1,Ritter Angela2,Kelly Scott A3,Pourhassan Nader Z3,Tiwary Meenakshi4,Sacha Jonah B4,Hansen Scott G4,Recknor Christopher3,Yang Otto O56

Affiliation:

1. Arthritis & Rheumatic Disease Specialties , Aventura, Florida , USA

2. Center for Advanced Research & Education , Gainesville, Georgia , USA

3. CytoDyn , Vancouver, Washington , USA

4. Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University , Beaverton, Oregon , USA

5. Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California–Los Angeles , Los Angeles, California , USA

6. Department of Microbiology, Immunology, and Molecular Genetics, University of California—Los Angeles , Los Angeles, California , USA

Abstract

Abstract In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.

Funder

Oregon Health & Science University

CytoDyn

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference14 articles.

1. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact.;Davis;EClinicalMedicine,2021

2. The expanding therapeutic perspective of CCR5 blockade.;Vangelista;Front Immunol,2017

3. Unraveling risk genes of COVID-19 by multi-omics integrative analyses.;Baranova;Front Med (Lausanne),2021

4. Regulatory noncoding and predicted pathogenic coding variants of CCR5 predispose to severe COVID-19.;Cantalupo;Int J Mol Sci,2021

5. Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity.;Cuesta-Llavona;Int Immunopharmacol,2021

Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3